UMIZORTAMIG
UNII KX8KZX98PB
Substance Identification & Data
This profile provides standardized clinical and technical data for Umizortamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) KX8KZX98PB.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2599198-83-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
KX8KZX98PB
2599198-83-9
N/A
Detailed Substance Profile
Preferred Name
UMIZORTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
12292
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Umizortamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Umizortamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Umizortamig
Common Names & Synonyms
Immunoglobulin, tetraspecific, anti-(human CD3 antigen ε-chain and γ-chain) (human-Oryctolagus cuniculus clone 284A10 single-chain variable fragment VL-(GGGGS)4-VH) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin G1 anti-(human epidermal growth factor receptor variant III) [495-alanine,496-alanine,498-alanine,583-alanine,de-707-lysine] (human-Mus musculus monoclonal ABT-806 γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human programmed death-ligand 1) (human-Oryctolagus cuniculus clone PL221G5 single-chain variable fragment VH-(GGGGS)4-VL) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human tumor necrosis factor receptor TNFRSF9) (human-Oryctolagus cuniculus clone 420H5 single-chain variable fragment VH-(GGGGS)4-VL), disulfide with human-Mus musculus monoclonal ABT-806 κ-chain, dimer
immunoglobulin scFv-G1-scFv-scFv_L-kappa, anti-[Homo sapiens EGFRvIII (epidermal growth factor receptor (receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) variant III)], anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4) and CD3G], anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PD-L1, PDCD1L1, B7 homolog 1, B7 homologue 1)] and anti-[Homo sapiens TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137 (4-1BB, CD137). 41BB)], humanized and chimeric monoclonal antibody, tetraspecific, tetravalent
scFv-G1-scFv-scFv fused heavy chain humanized and chimeric (1-1231)[scFv kappa-heavy anti-CD3E and CD3G humanized (1-252) [V-KAPPA (Homo sapiens IGKV1-5*01 (90.1%) -IGKJ4*01 (90.9%), CDR-IMGT[6.3.14] (27-32.50-52.89-102)) (1-112) -20-mer tetrakis(tetraglycyl-seryl)linker (113-132) -VH (Homo sapiens IGHV3-66*01 (86.6%) -(IGHD)-IGHJ1*01 (100%), CDR-IMGT [8.7.14] (158-165.183-189.228-241)) (133-252)] -10-mer bis(tetraglycyl-seryl) linker (253-262) -gamma-1 heavy chain anti-EGFRvIII chimeric (263-707) [VH Musmus/Homsap (Mus musculus IGHV3-2*02 (94.82%) -(IGHD) -IGHJ3*01 (92.9%)/Homo sapiens IGHV4-30-4*01 (72.9%) -(IGHD) -IGHJ4*01 (85.7%), CDR-IMGT [9.7.9] (288-296.314-320.359-367)) (263-378) -Homo sapiens IGHG1*01v, G1m17, 1>G1m3,1, G1v14-1 CH2 A1.3, A1.2, A1, G1v20 CH2 A105 (CH1 R120(475) (379-476), hinge 1-15 (477-491), CH2 L1.3>A (495), L1.2>A (496), G1>A (498), K105>A (583) (492-601), CH3 D12 (617), L14 (619) (602-706), CHS K2>del (707)) (379-707)] -10-mer bis(tetraglycyl-seryl) linker (708-717) -scFv heavy-kappa anti-CD274 humanized (718-969) [VH(Homo sapiens IGHV3-23*01 (84.0%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [9.9.13] (743-751.769-777.816-828)) (718-839) -20-mer tetrakis(tetraglycyl-seryl) linker (840-859) -V-KAPPA (Homo sapiens IGKV1-5*03 (91.5%) -IGKJ4*01 (100%), CDR-IMGT [6.3.12] (886-891.909-911.948-959)) (860-969)] -10-mer bis(tetraglycyl-seryl) linker (970-979)-scFv heavy-kappa anti-TNFRSF9 humanized (980-1231) [VH (Homo sapiens IGHV3-66*01 (85.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT[9.9.12] (1004-1012.1030-1038.1077-1088)) (980-1099) -20-mer tetrakis(tetraglycyl-seryl) linker (1100-1119) -V-KAPPA (Homo sapiens IGKV1-5*03 (87.2%) -IGKJ4*01 (100%), CDR-IMGT [6.3.14] (1146-1151.1169-1171.1208-1221)) (1120-1231)]]; (481-214')-disulfide with kappa light chain anti-EGFRvIII chimeric (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV14-100*01 (93.7%) -IGKJ1*01 (100%)/Homo sapiens IGKV1-12*01 (63.2%) -IGKJ4*01 (90.9%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01(100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (487-487'':490-490'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
umizortamig [INN]
